When to Test IGF-1
Measure IGF-1 in all patients with incidentally discovered pituitary adenomas (regardless of size), in patients with typical acromegalic features (acral/facial changes), and in those with a cluster of associated conditions even without classic features 1, 2.
Primary Indications for IGF-1 Testing
Pituitary Lesions (Strongest Indication)
- All incidental sellar lesions require IGF-1 screening at initial presentation, irrespective of size 1
- This includes incidentally discovered empty sella
- Symptoms may not correlate with pituitary dysfunction, making universal screening essential
- Growth hormone-secreting adenomas comprise 2-9% of pituitary incidentalomas 1
Clinical Acromegaly Suspicion
Measure IGF-1 when patients present with:
- Typical acromegalic features: Acral enlargement (hands/feet), facial changes (frontal bossing, prognathism, coarse facial features) 2
- These patients warrant strong recommendation for testing (Grade 1 evidence)
Atypical Presentations
Consider IGF-1 testing when patients have SEVERAL of these conditions clustered together 2:
- Sleep apnea syndrome
- Type 2 diabetes mellitus
- Debilitating arthritis
- Carpal tunnel syndrome
- Hyperhidrosis
- Hypertension
Important caveat: Recent high-quality evidence shows routine IGF-1 screening in poorly controlled type 2 diabetes alone has very limited yield (0.39% detection rate) 3. Testing should be reserved for those with clinical features or phenotypic suspicion, not diabetes alone.
Follow-Up Testing Scenarios
Monitoring Known Pituitary Lesions
- Repeat IGF-1 at 1-2 years for all microadenomas and macroadenomas 1
- Earlier repeat testing if new clinical symptoms develop
- Mandatory repeat with any enlarging adenoma 1
- New hypopituitarism can develop without concurrent lesion growth
Post-Surgical Assessment
For patients with acromegaly who undergo surgery, IGF-1 at 6 weeks postoperatively is equally predictive of surgical outcomes as testing at 3-6 months in most cases (96.5% concordance) 4.
Critical Testing Considerations
Interpretation Pitfalls
IGF-1 levels must be compared to age-appropriate and sex-appropriate reference ranges 2:
- IGF-1 decreases with age after adolescence
- Significant interassay variability exists (30% misdiagnosis rate across different laboratories) 2
- Know your specific laboratory's assay
False results occur with 2:
- Pregnancy and late adolescence (false positives)
- Hepatic/renal failure (falsely low)
- Hypothyroidism (falsely low)
- Malnutrition, severe infection (falsely low)
- Poorly controlled diabetes (falsely low)
- Oral estrogens (falsely low due to hepatic GH resistance)
Confirmation Required
Never diagnose acromegaly on IGF-1 alone. When IGF-1 is elevated or equivocal, confirm with oral glucose tolerance test showing failure to suppress GH to <1 mg/L 2. Random GH levels should not be used for diagnosis due to episodic secretion 2.
What NOT to Do
- Do not screen large populations with common comorbidities (diabetes, hypertension, sleep apnea) in isolation—there is no compelling evidence supporting this approach 2, 3
- Do not rely on random GH levels for diagnosis 2
- Do not use IGF-1 as a standalone test for growth hormone deficiency in adults—dynamic testing is required 5